Endocrine resistant breast cancer: brain metastasis.
Endocrine resistant breast cancer
brain oncology
emerging therapeutics
metastasis
Journal
Exploration of targeted anti-tumor therapy
ISSN: 2692-3114
Titre abrégé: Explor Target Antitumor Ther
Pays: United States
ID NLM: 101770662
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
5
5
2022
Statut:
ppublish
Résumé
Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to rise, the rate of brain metastasis has also increased. For single lesions or a large symptomatic lesion with other smaller lesions, surgical resection is a viable option in non-eloquent regions. Stereotactic radiosurgery is a great option for post-operative therapy or for 10 or fewer small lesions (< 3 cm in size). Whole-brain radiation can be used sparingly for large tumor burdens but should encompass hippocampus sparing techniques. Chemotherapy options have remained relatively limited due to decreased permeability of the blood-brain barrier. Emerging monoclonal antibody treatments have offered initial promise, especially for endocrine resistant breast cancer metastasis.
Identifiants
pubmed: 35505937
doi: 10.37349/etat.2022.00081
pmc: PMC9060566
mid: NIHMS1799628
doi:
Types de publication
Journal Article
Langues
eng
Pagination
240-251Subventions
Organisme : NINDS NIH HHS
ID : R25 NS108939
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of interest The author declares that there are no conflicts of interest.
Références
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
Breast. 2019 Nov;48 Suppl 1:S26-S30
pubmed: 31839155
Br J Cancer. 2021 Jan;124(1):142-155
pubmed: 33250512
Nat Cell Biol. 2005 Feb;7(2):126-36
pubmed: 15654331
Nat Commun. 2016 May 13;7:11579
pubmed: 27174596
Endocr Relat Cancer. 2020 Dec;27(12):671-683
pubmed: 33112819
Acta Pharmacol Sin. 2010 Mar;31(3):361-6
pubmed: 20154714
Oncogene. 2010 May 20;29(20):2983-95
pubmed: 20208560
Clin Cancer Res. 2021 Mar 1;27(5):1220-1226
pubmed: 33055172
Clin Neurol Neurosurg. 2018 Oct;173:61-64
pubmed: 30086430
Cancers (Basel). 2021 Mar 03;13(5):
pubmed: 33802424
Breast Cancer Res. 2021 Aug 15;23(1):85
pubmed: 34392831
Biochem Pharmacol. 2021 Aug;190:114635
pubmed: 34058187
Nat Med. 2010 Jan;16(1):116-22
pubmed: 20023634
Oncology (Williston Park). 2019 Aug 23;33(8):
pubmed: 31469897
Ann Transl Med. 2021 Nov;9(22):1704
pubmed: 34988213
Radiother Oncol. 2020 Jan;142:27-35
pubmed: 31563407
Ther Adv Med Oncol. 2020 Jun 30;12:1758835920936151
pubmed: 32655700
Cancer Med. 2018 Aug;7(8):3820-3833
pubmed: 29992751
Breast Care (Basel). 2020 Aug;15(4):347-354
pubmed: 32982644
Exp Hematol Oncol. 2015 Nov 24;4:33
pubmed: 26605131
Int J Oncol. 2009 Jul;35(1):57-68
pubmed: 19513552
Front Pharmacol. 2021 Mar 15;12:628690
pubmed: 33790792
ESMO Open. 2022 Feb;7(1):100343
pubmed: 34995893
Front Oncol. 2021 Mar 18;11:639480
pubmed: 33816283
Nat Commun. 2021 Aug 25;12(1):5112
pubmed: 34433817
Clin Cancer Res. 2020 Oct 15;26(20):5310-5319
pubmed: 32694159
Neurosurgery. 2019 Mar 1;84(3):E152-E155
pubmed: 30629227
Mol Med. 2016 Sep;22:32-40
pubmed: 26837070
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18060-5
pubmed: 23077249
Clin Cancer Res. 2019 Jun 1;25(11):3374-3383
pubmed: 30796030
Int J Mol Sci. 2021 Nov 14;22(22):
pubmed: 34830174
Magn Reson Med. 2006 Nov;56(5):1001-10
pubmed: 17029229
Int J Mol Sci. 2020 Dec 26;22(1):
pubmed: 33375317
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
Cancers (Basel). 2021 Sep 18;13(18):
pubmed: 34572912
Mol Cancer Res. 2010 Jan;8(1):24-34
pubmed: 20068070
Genes Dev. 2018 Sep 1;32(17-18):1141-1154
pubmed: 30181360
Clin Cancer Res. 2010 Dec 1;16(23):5664-78
pubmed: 20829328
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6786-6793
pubmed: 32633370
Front Oncol. 2014 Apr 14;4:64
pubmed: 24782981
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Radiat Oncol. 2019 Mar 14;14(1):45
pubmed: 30871597
Sci Rep. 2020 Mar 9;10(1):4340
pubmed: 32152433
Cell Death Dis. 2020 Sep 24;11(9):797
pubmed: 32973135
J Cancer. 2019 Aug 29;10(22):5504-5517
pubmed: 31632494
Ecancermedicalscience. 2013 Apr 18;7:308
pubmed: 23634178
Front Endocrinol (Lausanne). 2019 May 24;10:245
pubmed: 31178825
Ann Oncol. 2014 Jun;25(6):1116-21
pubmed: 24685829
FEBS Lett. 2001 Oct 19;507(1):59-66
pubmed: 11682060
Ann Oncol. 2019 Jan 1;30(1):115-123
pubmed: 30423024
Neurosurgery. 2005 May;56(5):1021-34; discussion 1021-34
pubmed: 15854250
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Breast Cancer Res. 2020 Feb 3;22(1):16
pubmed: 32014063
BMC Health Serv Res. 2020 Jan 31;20(1):73
pubmed: 32005232
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Breast Care (Basel). 2013 Aug;8(4):256-62
pubmed: 24415978
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
NPJ Breast Cancer. 2018 Aug 30;4:29
pubmed: 30182054
Int J Mol Sci. 2021 Jan 05;22(1):
pubmed: 33466512
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
Ther Adv Med Oncol. 2021 Apr 22;13:17588359211009002
pubmed: 33995593
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
JCO Precis Oncol. 2021 Jul 09;5:
pubmed: 34632252
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Oncotarget. 2016 Mar 29;7(13):16619-35
pubmed: 26918606
Sci Rep. 2016 Dec 20;6:39460
pubmed: 27995973
Nat Med. 2018 Jul;24(7):1024-1035
pubmed: 29892069
Breast Care (Basel). 2016 Jun;11(3):167-73
pubmed: 27493615
Front Mol Neurosci. 2011 Dec 02;4:51
pubmed: 22144946
Clin Neurol Neurosurg. 2021 Jul;206:106645
pubmed: 33984752
Clin Cancer Res. 2020 Apr 15;26(8):1820-1828
pubmed: 31937616
Oncologist. 2021 Oct;26(10):835-844
pubmed: 34105210
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716